PLoS Genetics (Apr 2011)

PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease.

  • Julie Turnbull,
  • Anna A DePaoli-Roach,
  • Xiaochu Zhao,
  • Miguel A Cortez,
  • Nela Pencea,
  • Erica Tiberia,
  • Mark Piliguian,
  • Peter J Roach,
  • Peixiang Wang,
  • Cameron A Ackerley,
  • Berge A Minassian

DOI
https://doi.org/10.1371/journal.pgen.1002037
Journal volume & issue
Vol. 7, no. 4
p. e1002037

Abstract

Read online

Lafora disease is the most common teenage-onset neurodegenerative disease, the main teenage-onset form of progressive myoclonus epilepsy (PME), and one of the severest epilepsies. Pathologically, a starch-like compound, polyglucosan, accumulates in neuronal cell bodies and overtakes neuronal small processes, mainly dendrites. Polyglucosan formation is catalyzed by glycogen synthase, which is activated through dephosphorylation by glycogen-associated protein phosphatase-1 (PP1). Here we remove PTG, one of the proteins that target PP1 to glycogen, from mice with Lafora disease. This results in near-complete disappearance of polyglucosans and in resolution of neurodegeneration and myoclonic epilepsy. This work discloses an entryway to treating this fatal epilepsy and potentially other glycogen storage diseases.